Inhibrx Biosciences (INBX) Current Leases (2023 - 2026)

Inhibrx Biosciences (INBX) has reported Current Leases for 3 consecutive years, with $2.3 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Current Leases rose 45.83% year-over-year to $2.3 million; the TTM figure through Dec 2025 stood at $2.3 million (up 45.83% YoY), while the FY2025 annual figure was $2.3 million, up 45.83% from the prior year.
• Current Leases improved to $2.3 million in Q4 2025 per INBX's latest filing, from $2.2 million in the prior quarter.
• Across five years, Current Leases topped out at $2.3 million in Q4 2025 and bottomed at $1.6 million in Q4 2024.
• Historically, Current Leases has averaged $2.0 million across 3 years, with a median of $2.1 million in 2023.
• Annual changes were most pronounced in 2024 — Current Leases slipped 22.69% — and 2025, when it surged 45.83%.
• Inhibrx Biosciences' Current Leases stood at $2.1 million in 2023, then dropped by 22.69% to $1.6 million in 2024, then surged by 45.83% to $2.3 million in 2025.
• Business Quant data shows INBX's Current Leases at $2.3 million in Q4 2025, $2.2 million in Q3 2025, and $2.2 million in Q2 2025.